Nalaganje...
P-147 Final analysis: phase II trial of Irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type mCRC: HGCSG0902. -comparison of administration interval in cetuximab treatment
Shranjeno v:
| izdano v: | Ann Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Oxford University Press
2016
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4983925/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw199.141 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|